BTL, a leader in medical innovation, is proud to announce a major milestone: the successful treatment of the first patients suffering from atrial fibrillation (AF) in a groundbreaking study using a next-generation catheter designed to improve the way AF is treated.
PRAGUE, Dec. 3, 2024 /PRNewswire/ -- As the prevalence of atrial fibrillation (AF) continues to rise, BTL has announced the successful treatment of the first six patients in the first-in-human feasibility study using a next-generation catheter system designed to streamline AF ablation. This new catheter technology is based on pulsed-field ablation (PFA), a cutting-edge approach that promises to make AF treatment safer, faster, and more effective. The system is undergoing clinical trial under the leadership of renowned experts in cardiology: Dr. Vivek Reddy, Director of Cardiac Arrhythmia Services at Mount Sinai Hospital, NY, Dr. Petr Neuzil, Chief of Cardiology at Na Homolce Hospital, Prague and Dr. Štěp